Clinical trials
Phase 1 Carcinoma, Renal Cell trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
22 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 3 |
| 2025 | 1 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Active, not recruiting | 4 |
| Recruiting | 4 |
| Terminated | 4 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 6 |
| Exelixis | 3 |
| Incyte Corporation | 2 |
| Pfizer | 2 |
| ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 1 |
| Bristol-Myers Squibb | 1 |
| Eli Lilly and Company | 1 |
| HiFiBiO Therapeutics | 1 |
| Hoffmann-La Roche | 1 |
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Renal Cell | 22 |
| Carcinoma, Non-Small-Cell Lung | 10 |
| Colorectal Neoplasms | 9 |
| Neoplasms | 6 |
| Melanoma | 5 |
| Carcinoma, Hepatocellular | 4 |
| Kidney Neoplasms | 4 |
| Squamous Cell Carcinoma of Head and Neck | 4 |
| Stomach Neoplasms | 4 |
| Breast Neoplasms | 3 |
Trials
Showing 1 to 22 of 22. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.